Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | A pharmacoeconomic analysis of multiple myeloma treatment

Rafael Fonseca • 1 Jun 2018
ASCO 2018
Multiple Myeloma

The treatment of multiple myeloma (MM) can be very costly. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses whether patients are able to afford medication for MM, whether they face any financial problems, and finally if MM drugs are worth their cost.

More from Rafael Fonseca

0:57
Optimal sequencing of therapies for transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Dec 2023
1:04
The value of MRD in transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Jan 2024
2:10
DRd versus VRd in patients with MM: a real-world retrospective analysis
Rafael Fonseca • 9 Dec 2023
1:52
Secondary cytogenetic abnormalities in MM: prognostic value of chromosome 1q gain vs amplification
Rafael Fonseca • 9 Dec 2023

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals